Association Between Non-alcoholic Fatty Liver Disease and Iron Status

(BAFLA- Barzilai Fatty Liver and Iron Metabolism Study)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01307254

Acronym

BAFLA

Enrollment

Registered

2011-03-02

Start date

2011-01-31

Completion date

2013-07-31

Last updated

2012-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD - Non Alcoholic Fatty Liver Disease

Brief summary

The investigators hypothesize that low iron storages protects from and down-grades non-alcoholic fatty liver disease. The aim of the study is to show the association between the severity of Non-alcoholic fatty liver disease to low iron status.

Detailed description

Patients that will pass a CT scan that includes the abdomen will be asked to participate at our study. These patients will be divided into two groups - with and w/o fatty liver. The severity of fatty liver will be determined using the CT scan (as well as other parameters, such as the size of subcutaneous fat layer). Within 72 hours from the scan, a venous blood test will be taken from the enrolled patients (together with a BMI calculation and a blood pressure measurements). In the blood test we will examine liver functions, iron status etc. This is a preliminary study that will aid in planning future strategies to treat or even prevent fatty liver (one of the epidemics of our century).

Interventions

PROCEDUREblood analysis

A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age\>18 * BMI\>25

Exclusion criteria

* pregnancy * unable to sign an informed consent (legally) * known solid/hematological malignancy * hemoglobinopathy or myelodysplastic disease (not including G6PD deficiency) * active or carrier of viral hepatitis * treated a drug the cause fatty liver (eg. amiodarone, tetracyclin, HAART, steroid treatment \> 3 months) * consumption of \> 120g ethanol per week * primary liver disease (eg. glycogen storage disease) * CRP\>20 * acute intoxication * surgery in previous 7 days

Design outcomes

Primary

Measure	Time frame
grade of fatty liver disease	1 year

Countries

Israel

Contacts

Primary ContactAlbert Grinshpun

albert.grinshpun@mail.huji.ac.il972-54-5615563

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026